Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amir Azarbal

Cardiovascular Disease Jacksonville, FL Medical Doctor

NPI 1679830632 CMS profile 1389068

3900 University Blvd S, Jacksonville, FL 32216

Open in the dashboard

General payments

$28,002

335 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$18,612 paid to institutions, not to them · program year 2024

Through program year 2025, Amir Azarbal of Jacksonville, FL is reported in the CMS Open Payments database as having received $28,002 across 335 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $18,612 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,041 153
2024 General $3,059 48
2023 General $4,915 62
2022 General $1,920 29
2021 General $516 26
2020 General $43 2
2019 General $11,508 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amir Azarbal
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Amir Azarbal were reported at $6,041. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Amir Azarbal Cardiovascular Disease median Middle half National median
2019 $11,508 $450 $127–$1,392 $163
2020 $43 $242 $77–$751 $114
2021 $516 $335 $101–$1,037 $132
2022 $1,920 $395 $121–$1,211 $149
2023 $4,915 $443 $136–$1,283 $160
2024 $3,059 $450 $136–$1,323 $164
2025 $6,041 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic Vascular, Inc. $10,534 8 payments
  2. Abiomed $3,522 29 payments
  3. Abbott Laboratories $3,468 41 payments
  4. Edwards Lifesciences Corporation $2,339 18 payments
  5. Inari Medical, Inc. $1,558 21 payments
  6. Boston Scientific Corporation $970 12 payments
  7. Biosense Webster, Inc. $957 15 payments
  8. Medtronic, Inc. $740 19 payments
  9. Stryker Corporation $613 72 payments
  10. CVRx, Inc. $389 8 payments
  11. Other $2,912 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,035 303 payments
  2. Grant $10,322 1 payment
  3. Travel and Lodging $3,627 30 payments
  4. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. CoreValve Evolut $10,450 7 payments
  2. Impella $2,417 19 payments
  3. CT THROMBECTOMY SYSTEM KIT $1,774 34 payments
  4. FLOWTRIEVER CATHETER, S $1,774 34 payments
  5. MITRACLIP $1,096 11 payments
  6. NAVITOR $939 8 payments
  7. Carto 3 $900 14 payments
  8. SAPIEN 3 Ultra RESILIA $670 6 payments
  9. WATCHMAN FLX $516 6 payments
  10. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $416 3 payments
  11. Other $6,712 219 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

157

Median for Interventional Cardiology: 2,236

Drug cost

$31,932

Median for Interventional Cardiology: $380,412

Branded share of claims

39.5%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 24 $20,822
Eliquis Apixaban Brand 14 $9,978
Clopidogrel Clopidogrel Bisulfate Brand 24 $262
Bumetanide Generic 15 $254
Atorvastatin Calcium Generic 20 $176
Metoprolol Succinate Generic 12 $164
Metoprolol Tartrate Generic 14 $160
Furosemide Generic 21 $95
Pantoprazole Sodium Generic 13 $20

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$482,515

Of which drugs: $1,694

Medicare patients

780

Average age 74

Services billed

5,203

378 women, 402 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Arthritis 57%
Diabetes 47%
Heart failure 35%
Chronic kidney disease 35%
Atrial fibrillation 31%
COPD 30%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 63 252 $1,424
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 28 2,480 $270

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $46
$46 — —
Repatha
  • Amgen Inc. $34
$34 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $18
$18 24 —
VERQUVO
  • Merck Sharp & Dohme Corporation $15
$15 — —
VYNDAQEL
  • PFIZER INC. $14
$14 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

335 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record